Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a peptide injection help rebuild Insulin-Making cells?

NCT ID NCT02538848

Knowledge-focused Sponsor: HighTide Therapeutics (Hong Kong) Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called HTD4010, a synthetic version of a natural peptide that may help the pancreas regenerate insulin-producing cells. The study enrolls healthy, non-diabetic volunteers to receive single ascending doses of the drug or a placebo. The main goal is to assess how safe and tolerable the drug is, and how the body processes it, before any potential future studies in people with type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HTD4010, an experimental injectable analog of the INGAP peptide
What this could lead to
If safe and well-tolerated, HTD4010 could pave the way for future studies exploring its potential to help regenerate insulin-producing cells, possibly offering a new approach to treating type 2 diabetes.
What could go wrong
This is an early, first-in-human study focused on safety, not effectiveness. The drug may cause unexpected side effects or fail to show promise in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

32 people

The number who actually took part.

Start date

Oct 2015

Finished

Mar 2016

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For volunteers in SAD: Inclusion Criteria: 1. Body mass index (BMI) ≥18.0 to ≤ 30.0 kg/m2 2. Non-diabetic, fasting plasma glucose \< 5.6 mmol/L 3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for ≥12 months. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, the participant and his partner must be using an acceptable, highly effective, contraceptive method from screening and for a period of 60 days after the last dose of Study Drug. 4. Ability to provide written informed consent. Exclusion Criteria: 1. Systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>90 mmHg at screening. 2. Pregnant or lactating women 3. Participation in an investigational study within 30 days prior to dosing or 5 half-lives within the last dose of investigational product whichever is longer. 4. Current use of any prescription or over-the-counter (OTC) medications, including herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives, whichever is longer. Use of ≤2g paracetamol per day is allowed prior to and during the study at Investigator discretion. 5. Any use of non-steroid anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing. 6. History of any major surgery within 6 months prior to Screening 7. History of any serious adverse reaction or hypersensitivity to any of the product components. 8. Use of parenterally administered proteins or antibodies within 12 weeks of screening. etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus

Contacts and locations

Locations

  • Linear Clinical Research Limited

    Perth, WA6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.